Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) Patients
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: Nivolumab|DRUG: Cisplatin|DRUG: Low dose doxorubicin
Sponsor: The Netherlands Cancer Institute
Collaborators: Bristol-Myers Squibb